الفهرس 
List of figuresOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
In this study 28 cases diagnosed with different types of lymphoid malignancies and had chronic HCV infection ( positive HCV RNA PCR ) at the time of lymphoid malignancy diagnosis were randomized to receive sofosbuvir/daclatasvir combination either concomitant with or after the end of chemotherapy treatment. Fifteen patients received DAAs concomitantly with chemotherapy (group A), and 13 patients received DAAs after the end of chemotherapy treatment (group B).
Twenty-three patients were diagnosed with different types of lymphoid malignancies more than or equal to 1 year post sofosbuvir / daclatasvir treatment (group C).
The characters of these lymphoid malignancies and their outcome (RR, DFS, and OS) are also studied in comparison with HCV negative lymphoid malignancies (group D).
The most common diagnosis was DLBCL followed by HL , CLL/SLL , FL , MALT lymphoma , MM and SMZL , with HCV percentage being higher in indolent lymphoma and MM than in aggressive lymphoma ( the highest in SMZL (66.7 %) followed by FL (50%) , MM (40%) , CLL/SLL (38.5%) , and MALT lymphoma (33.3%) and lowest in HL (3.6%)).
Conclusion:
DAAs mainly sofosbuvir/daclatasvir improve the outcome of different types of lymphoid malignancies (RR, DFS, OS) in patients with HCV infection associated lymphoid malignancies when given either concomitant or after the end of chemotherapy to be non-significantly different from HCV negative lymphoid malignancies, the DFS and OS are markedly improved even better than HCV negative lymphoid malignancies when DAAs are given after the end of chemotherapy.
Also a large number of patients are diagnosed with different types of lymphoid malignancies shortly after the end of DAAs treatment for chronic HCV infection , the outcome of these types of malignancies is not statistically different from HCV negative lymphoid malignancies and the claim that sofosbuvir might has relation to this can’t be confirmed in this study.